Ovarian Cancer Treatment

Purdue Research Park-based Endocyte Inc. presented data about its potential treatment for advanced ovarian cancer before the European Society of Gynaecologic Oncology in Belgrade, Serbia. Results are from a Phase 2a clinical trial for EC145. The company says in 49 women with advanced-stage ovarian cancer, EC145 was shown to have anti-tumor activity in a significant percentage of participants. Endocyte says the results are now being evaluated...